XADAGO®

Hold Company

MDD US

Learn More

Dosage and Administration

TABLET;ORAL

Specification

EQ 50MG BASE; EQ 100MG BASE

Indication

XADAGO® can be used as an adjunct to levodopa/carbidopa in patients with "onset" Parkinson's disease (PD).

Use

Instructions for Use

API

SAFINAMIDE MESYLATE

API Structure

We Supply

SAFINAMIDE MESYLATE

Note:

In-house Standard
Facility GMP
DMF is preparing

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
8076515	2028/12/10
8278485	2027/6/8
8283380	2031/3/21

API Patent

Patent No	Expiration Date
8076515	2028/12/10
8278485	2027/6/8

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.